Overview
In a changing and expanding world, this is still the only forum designed for QPPVs by QPPVs, now celebrating its 16th year and still going strong.
Back in a face-to-face format, it brings together QPPVs from all over the world to discuss how to harmonise international QPPV roles. Key trends requiring QPPV awareness, input and oversight are discussed in a high-level and neutral approach.
This year’s objectives have been shaped by feedback provided by participants from the past 15 meetings. We will discuss pragmatic approaches to modern technology and how this will impact the QPPV role in multiple regions.
The Forum is continually supported by key regulators and lives from interaction. Take this opportunity to raise questions and bring your challenging issues to the group in an informal and interactive environment.
Featured Topics
- Pharmacovigilance Guidelines and Regulations Updates (EU, non-EU, Global)
- Globalisation of PSMF: Practical Implementation
- Lessons Learnt from the Experiences with COVID-19 Vaccines
- Future Changes and Challenges in PV
- Data Science and Standards: Impact on Pharmacovigilance
- Patient Support Programmes
- Medical devices, Wearables, Combination Products
Who should attend?
- Global QPPVs/ Deputies
- Regulators
- Pharmacovigilance Consultants
- Directors of Pharmacovigilance Oversight and Standards
- Drug Safety Managers/Leaders
- Auditors
- Medical and Regulatory Affairs Experts
- Aspiring PV Specialists/QPPVs
Learning objectives
- Hear the latest updates and hot topics relating to the role of the QPPV
- Explore long term PV visions, future directions of the ‘PV world’, and potential impact on the role of the QPPV
- Network with colleagues and meet regulators
- Learn from and share experience and ideas with like-minded QPPVs in a neutral environment
- Better understand regulatory and inspectorate expectations globally
- Examine current challenges and share potential solutions
Program Committee
-
Angela Van Der Salm, PhD, MSc • Director Pharmacovigilance, Managing partner
DADA Consultancy BV, Netherlands -
Magnus Ysander, MD • EU & UK QPPV & Head Pharmacovigilance Excellence
AstraZeneca, Sweden -
Shahinaz Badr • Independent Consultant
United Arab Emirates -
Vicki Edwards, RPh • Vice President, Pharmacovigilance Excellence and International QPPV
AbbVie, Inc., United Kingdom -
Gemma Jimenez Sese • CORPORATE DRUG SAFETY HEAD - EUQPPV
ALMIRALL, S.A., Spain -
Maarten Lagendijk, MSc • Deputy EU QPPV
MSD B.V., Netherlands -
Elspeth McIntosh, MBA, RN • Director
Castle Pharmacovigilance Ltd, United Kingdom -
Katarzyna Swiderek, MPharm, RPh • Director, Safety Evaluation Risk Management (SERM)
GlaxoSmithKline, Poland -
Kiernan Trevett, MSc • Principal Quality Lead, PDQ Quality Assurance Process GVP
Roche, United Kingdom -
Sophie Radicke, MSc • Senior Pharmacovigilance Inspector
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom -
Nicolas Tsiakkas, MD • Scientific Director
Medwork Pharma Research & Consulting, Greece -
Willemijn van der Spuij, MSc • Executive Director, WorldWide Patient Safety International, Europe
Bristol-Myers Squibb, Switzerland
